Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Women's Cancer Study Group GmbH
With
Agendia
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women with histologically proven invasive stage 1 and 2 breast cancer
Hormone receptor positive according to local standards
HER2 negative - i.e. IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)
Axillary lymph node status: 0-3 involved (macro metastases i.e. \>2mm OR micro metastases i.e. \>0.2-2mm)
≥ 18 years of age at time of consent
Patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity
Written informed consent
You may not be if
≥4 involved axillary nodes
Multi-centric disease with more than 2 clinically relevant lesions
HR negative OR HER2 positive/amplified (locally assessed)
Previous diagnosis of malignancy unless disease free for 10 years
Metastatic disease
Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC criteria
Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer
Clareo Health | PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)
